PTHS · Pelthos Therapeutics Inc.
$20.71
-0.30 (-1.43%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— cleared May 14, 2026
The latest filing states the doubt was alleviated.
“in prior periods, management disclosed substantial doubt about the Company's ability to continue as a going concern. The conditions and events that previously raised substantial doubt have been alleviated by management's plans and actions.”View the 10-Q filed May 14, 2026
Market Cap
$84.95M
Shares
3.83M
Volume · Oct 1
7182
Avg daily vol (3M)
58.25K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$21.01
Open$21.26
Day$21.01–21.69
52W close$18.19–37.42
Avg vol 30d41K
Short int94K · 2.4% float · 2.2d
Short vol81%
Last earningsAug 13, 2026
DataFeb 2024–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$43.30M
Trailing 12 months
Net income (TTM)
−$86.39M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-133.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$24.19M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+442.9%
Year over year · more shares
Price change (1Y)
-25.0%
Trailing year
Short interest
2.4%
Latest settlement · 2.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−16%
below
Price vs 50-day avg
−17%
below
RSI (14)
38
neutral
MACD trend
Positive
52-week position
15%
near low
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−7%
trailing
YTD return
−32%
this year
Relative strength
−19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $25 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
+41% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.45% of float · ▼ -10.1% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
24 holders — near 2-yr high, broad support
Squeeze score
39
low risk · 0–100
Fundamentals
EPS growth
−61%
Y/Y
Free cash flow
$-22.7M
Buyback
$1.3M
authorized
Quant / Vol
risk profile
Volatility
79%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−16%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
38
Neutral
MACD trend
Positive
Bullish
52-week position
15%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $25 › 200d $25 — 50d above 200d
Institutional flow
Accumulating
+41% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.45% of float · ▼ -10.1% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
24 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $18
Now $21 · 15%
Range high $37
vs 200-day avg -16%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$5.7M | the second quarter of 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -23.42M
+2.76M Stock-based compensation
+2.3M Cost of goods sold basis step-up
+3.71M Change in fair value of convertible debt
+5.25M Non-recurring milestones
+2.39M Interest expense
+1.04M Amortization of intangible assets
+278K Depreciation
= Adjusted EBITDA -5.7M
|
|||
| Patients prescribed Zelsuvmi since launch | 25,000 | since commercial launch in July 2025 through the end of the seco | — |
| quarter over quarter percentage growth of net product revenues over the prior fiscal quarter | 45% | the three months ended June 30, 2026 filing | — |
|
|
|||
| Trailing twelve-month net product revenues | $42.3M | trailing twelve months ended June 30, 2026 | — |
|
|
|||
| Unique prescribers | 4,571 | the second quarter of 2026 | — |
| Unique prescribers (cumulative) | 7,414 | As of June 30, 2026 | — |
| Zelsuvmi units dispensed | 11,925 | the second quarter of 2026 | — |
| Zelsuvmi units dispensed (cumulative) | 29,126 | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PTHS
this stock
Pelthos Therapeutics Inc.
|
$84.95M | -32.2% | — | — | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PTHS | -10.7% | -15.4% | -7.0% | -12.8% | -32.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -10.0% | -15.5% | -19.1% | -12.2% | -44.1% |
Capital returns
Buyback programs
· 2 active
· as of Oct 22, 2024
Authorized (total)
$1.25M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.